A groundbreaking discovery has highlighted lithium—a drug long used to treat bipolar disorder and depression—as a potential therapy for autism spectrum disorder (ASD). This research, conducted by a team at the Center for Synaptic Brain Dysfunctions within the Institute for Basic Science (IBS) led by Director KIM Eunjoon, reveals that lithium can restore brain function and alleviate behavioral symptoms in animal models of ASD caused by mutations in the Dyrk1a gene.

ASD is a neurodevelopmental disorder affecting 2.8% of the global population, characterized by social deficits, repetitive behaviors, intellectual challenges, and anxiety. Because ASD imposes a heavy burden not only on the patients themselves but on their families and society as a whole, new therapeutic methods must be developed to treat the core symptoms of ASD. Despite its prevalence, there are no definitive treatments or preventive measures.

Among the many genetic risk factors for ASD, Dyrk1a mutations stand out as significant, leading to conditions such as Dyrk1a syndrome. Patients carrying Dyrk1a loss-of-function mutation have presented with ASD, microcephaly, language problems, social disability, and anxiety. The mouse model carrying Dyrk1a I48K truncation mutation (a human patient mutation), also mimics these phenotypes closely.

Frutto della ricerca di tre Istituti del Consiglio nazionale delle ricerche, è un innovativo catalizzatore a basso costo e ad alta efficienza per la produzione elettrolitica di idrogeno dall’acqua, denominato “Nigraf”. Descritto su Cell Reports Physical Science, incapsula al suo interno una struttura di ossido di grafene

 E’ pubblicato sulla rivista Cell Reports Physical Science lo studio relativo alla messa a punto di un nuovo catalizzatore a basso costo ed alta efficienza denominato “NiGraf” per la produzione elettrolitica di idrogeno dall’acqua, frutto di un team del Consiglio nazionale delle ricerche composto da ricercatori e ricercatrici dell’Istituto di cristallografia del Cnr di Bari (Cnr-Ic), dell’Istituto dei composti organometallici del Cnr di Firenze (Cnr-Iccom), e dell’Istituto per lo studio dei materiali nanostrutturati del Cnr di Palermo (Cnr-Ismn).